Paragon Associates & Paragon Associates II Joint Venture’s CareDx CDNA Stock Holding History

Paragon Associates & Paragon Associates II Joint Venture’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.68M	Buy	500,000 +125,000	+33%	+$2.37M	11.8%	3
2025 Q4	$7.07M	Sell	375,000 -50,000	-12%	-$838K	14.6%	2
2025 Q3	$6.18M	Buy	425,000 +205,597	+94%	+$2.93M	11.02%	3
2025 Q2	$4.29M	Buy	219,403 +169,403	+339%	+$3.01M	6.81%	6
2025 Q1	$888K	Buy	+50,000	New	+$1.08M	2.08%	10
2019 Q3	–	Sell	-25,000	Closed	-$900K	–	22
2019 Q2	$900K	Sell	25,000 -25,000	-50%	-$800K	0.69%	23
2019 Q1	$1.58M	Sell	50,000 -50,000	-50%	-$1.46M	1.49%	22
2018 Q4	$2.51M	Sell	100,000 -50,000	-33%	-$1.28M	3.34%	10
2018 Q3	$4.33M	Sell	150,000 -185,000	-55%	-$3.46M	4.93%	9
2018 Q2	$4.1M	Sell	335,000 -229,600	-41%	-$2.63M	5.33%	8
2018 Q1	$4.5M	Sell	564,600 -383,400	-40%	-$2.36M	6.56%	7
2017 Q4	$6.96M	Sell	948,000 -325,800	-26%	-$2.03M	5.79%	10
2017 Q3	$4.71M	Hold	1,273,800	–	–	4.02%	12
2017 Q2	$1.41M	Hold	1,273,800	–	–	1.61%	11
2017 Q1	$1.78M	Sell	1,273,800 -200,000	-14%	-$446K	1.92%	14
2016 Q4	$3.98M	Hold	1,473,800	–	–	5.29%	8
2016 Q3	$5.23M	Buy	1,473,800 +300,000	+26%	+$1.38M	6.05%	7
2016 Q2	$5.06M	Buy	1,173,800 +420,000	+56%	+$1.94M	4.95%	7
2016 Q1	$3.74M	Buy	753,800 +3,800	+0.5%	+$19.4K	3.13%	12
2015 Q4	$4.8M	Buy	750,000 +354,684	+90%	+$1.93M	4.1%	12
2015 Q3	$1.65M	Buy	+395,316	New	+$2.61M	1.76%	12

Other funds holding CDNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Paragon Associates & Paragon Associates II Joint Venture's CDNA Position: Q1 2026 in Review

Paragon Associates & Paragon Associates II Joint Venture increased its CareDx (CDNA) stake by 33% in Q1 2026, buying an estimated $2.37M and bringing the position to 500,000 shares worth $8.68M. The position accounts for 11.8% of the portfolio, ranked #3.

Paragon Associates & Paragon Associates II Joint Venture first reported a position in CDNA in Q3 2015 and has held it in 21 quarters since. 190 funds tracked by Wall St. Rank hold CDNA as of Q1 2026.

Paragon Associates & Paragon Associates II Joint Venture held 500,000 shares of CareDx worth $8.68M as of Q1 2026.
Paragon Associates & Paragon Associates II Joint Venture bought 125,000 CareDx shares in Q1 2026, an estimated $2.37M.
CareDx made up 11.8% of Paragon Associates & Paragon Associates II Joint Venture's portfolio in Q1 2026, its #3 holding.
Paragon Associates & Paragon Associates II Joint Venture first reported a position in CareDx in Q3 2015 and has held it in 21 quarters since.
190 funds tracked by Wall St. Rank held CareDx as of Q1 2026.

Based on Paragon Associates & Paragon Associates II Joint Venture's 13F filing for Q1 2026, filed 15 May 2026.